8-fluoro-5,11-dihydro-10H-dibenzo[a,d]cyclohepten-10-one | 543741-44-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: 8-fluoro-5,11-dihydro-10H-dibenzo[a,d]cyclohepten-10-one
• 英文别名: 8-fluoro-5,11-dihydro-10H-dibenzo[a,d]cycloheptene-10,11-dione；2-fluoro-5,10-dihydro-11H-dibenzo[a,d]cyclohepten-11-one；8-Fluoro-5H-dibenzo[a,d][7]annulen-10(11H)-one；6-fluorotricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaen-9-one
• CAS: 543741-44-2
• 化学式: C₁₅H₁₁FO
• 分子量: 226.25
• InChiKey: IVYDJPXELKPRQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8-fluoro-5,11-dihydro-10H-dibenzo[a,d]cyclohepten-10-one 在 selenium(IV) oxide 、 溶剂黄146 作用下， 反应 2.0h， 以67%的产率得到2-fluoro-5H-dibenzo[a,d]cycloheptene-10,11-dione
  参考文献：
  名称：

  强效大麻素受体拮抗剂利莫那班的亚甲基桥连类似物的合成和生物学评价

  摘要：

  合成了利莫那班的亚甲基桥接类似物，并评估了它们对 CB1 受体的活性。吡嗪衍生物显示出作为 CB1 拮抗剂的一些活性。

  DOI：

  10.1002/ejoc.200700960

文献信息

• [EN] SPIRO CYCLOPENTANE COMPOUNDS USEFUL AS ANTAGONISTS OF THE H1-RECEPTOR<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXO GROUP LTD

  公开号：WO2009016084A1

  公开（公告）日：2009-02-05

  This invention relates to novel spiro cyclopentane derivatives of formula (I) or a pharmaceutically acceptable salt thereof, for treating diseases and conditions of the central nervous system (CNS), in particular sleep disorders.

  该发明涉及公式（I）的新颖螺环戊烷衍生物或其药用盐，用于治疗中枢神经系统（CNS）的疾病和病症，特别是睡眠障碍。
• Diastereomeric Enols and Enol Derivatives of 8-Fluoro-5,11-dihydro-10H-dibenzo[a,d]cyclohepten-10-one with a Chiral 11-Substituent
  作者：Frans Compernolle、Suzanne Toppet、Thierry Brossette、Hua Mao、Mohamed Koukni、Tomasz Kozlecki、Bart Medaer、Michel Guillaume、Yolande Lang、Stef Leurs、Georges J. Hoornaert

  DOI：10.1002/ejoc.200500796

  日期：2006.3

  Aldol condensation of 8-fluoro-5,11-dihydro-10H-dibenzo[a,d]cyclohepten-10-one and (4S)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde provides access to the corresponding (E,Z)-α,β-unsaturated ketones with a (4R)-chiral 11-substituent. Subsequent hydrogenation affords a mixture of (11R)/(11S)-epimeric ketones, which undergoes base-catalysed equilibration resulting in selective crystallisation of the (11R)

  8-氟-5,11-二氢-10H-二苯并[a,d]环庚烯-10-酮和(4S)-2,2-二甲基-1,3-二氧戊环-4-甲醛的羟醛缩合提供了获得相应的 (E,Z)-α,β-不饱和酮具有 (4R)-手性 11-取代基。随后的氢化提供 (11R)/(11S)-差向异构酮的混合物，其经历碱催化平衡，导致 (11R) 差向异构体的选择性结晶。烯醇中间体和无环烯醇衍生物显示为两个缓慢相互转换的构象异构体，具有 10,11-二取代环的高反转势垒。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2006)
• Novel Substituted Tetracyclic Tetrahydrofuran, Pyrrolidine and Tetrahydrothiophene Derivatives and Their Use as a Medicament
  申请人：Megens Antonius Adrianus Hendrikus Petrus

  公开号：US20090023721A1

  公开（公告）日：2009-01-22

  This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT 2A and 5-HT 2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.

  这项发明涉及一种新的取代四环四氢呋喃、吡咯烷和四氢噻吩衍生物，其具有对5-HT2A和5-HT2C受体，特别是对多巴胺D2受体和去甲肾上腺再摄取抑制性能的结合亲和力，并且还包括根据本发明的化合物的制药组合物，其用作药物，特别是用于预防和/或治疗一系列精神和神经疾病，特别是某些精神病、心血管和胃动力障碍，以及其制备方法。根据本发明的化合物可以用一般式（I）表示，并包括其药学上可接受的酸或碱盐，其立体化学异构体形式，其N-氧化物形式和其前药，其中所有取代基在权利要求1中定义。
• Novel compounds
  申请人：Castiglioni Emiliano

  公开号：US20100190764A1

  公开（公告）日：2010-07-29

  This invention relates to novel Spiro cyclopentane derivatives of formula (I) or a pharmaceutically acceptable salt thereof, for treating diseases and conditions of the central nervous system (CNS), in particular sleep disorders.

  本发明涉及式(I)的新颖螺环戊烷衍生物或其药学上可接受的盐，用于治疗中枢神经系统(CNS)的疾病和病状，特别是睡眠障碍。
• NOVEL SUBSTITUTED TETRACYCLIC TETRAHYDROFURAN, PYRROLIDINE AND TETRAHYDROTHIOPHENE DERIVATIVES
  申请人：CID-NÚÑEZ José Maria

  公开号：US20100331325A1

  公开（公告）日：2010-12-30

  This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT 2A and 5-HT 2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.

  本发明涉及一种新型取代四环四氢呋喃、吡咯烷和四氢噻吩衍生物，具有与血清素受体结合亲和力，特别是5-HT2A和5-HT2C受体，以及多巴胺受体，特别是多巴胺D2受体和去甲肾上腺再摄取抑制性能，制备了包括本发明化合物的药物组合物，其用途作为药物，特别是用于预防和/或治疗一系列精神和神经系统疾病，特别是某些精神病、心血管和胃动力障碍，以及它们的生产过程。本发明的化合物可以用通式（I）表示，并包括其药学上可接受的酸或碱盐，其立体化学异构体形式，其N-氧化物形式和其前药，其中所有取代基如权利要求1所定义。